TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9181506

Group type: EXPERIMENTAL
Intervention: Percutaneous fixation using K‐wires, followed by casting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Closed reduction and casting
Number of subjects: 40
Study: 8243878

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (65 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin (0.1 IU/kg)
Number of subjects: 0
Study: 2938849

Group type: EXPERIMENTAL
Intervention: Selective inhibitor of thromboxane synthase, imidazo (1,5‐2) pyridine‐5‐hexanoic acid, administered under randomized, double‐blind, controlled conditions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (as a control for platelet cyclooxygenase inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term dosing with the synthetic inhibitor of thromboxane synthase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thromboxane synthase inhibitor
Number of subjects: 0
Study: 30709964

Group type: EXPERIMENTAL
Intervention: ALSDI (Amyotrophic Lateral Sclerosis Diagnostic Index) in the training cohort
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: ALSDI in the test cohort
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: ALSDI in Awaji negative patients
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: ALSDI in patients with predominantly lower motor neuron phenotype
Number of subjects: 407
Study: 28489288

Group type: EXPERIMENTAL
Intervention: Group CBT‐E (Enhanced Cognitive Behavioral Therapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group CBT‐E
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study: 25947202

Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention to reduce teenage pregnancy; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable; control group not specified.
Number of subjects: 0
Study: 23911273

Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose-adjustment (CDA) according to PR monitoring
Number of subjects: 177

Group type: COMPARATOR
Intervention: Prasugrel therapy
Number of subjects: 177
Study: 22235508

Group type: EXPERIMENTAL
Intervention: Biguanide (metformin 500 mg three times daily)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Statin (simvastatin 20 mg daily)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Biguanide (metformin)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Statin (simvastatin)
Number of subjects: 400
Study: 18977552

Group type: EXPERIMENTAL
Intervention: FibroMeter NAFLD
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: NAFLD fibrosis score (NFSA)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 235
Study: 16217850

Group type: EXPERIMENTAL
Intervention: Frequent assessment (16 postbaseline visits, twice-weekly for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional assessment (5 postbaseline visits at Weeks 1, 2, 4, 6, and 8)
Number of subjects: 0
Study: 15271855

Group type: EXPERIMENTAL
Intervention: 50% decreased vegetable intake (75 g/day) for 2 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Doubled vegetable intake (300 g/day) for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (healthy controls) receiving standard vegetable intake
Number of subjects: 28
Study: 11011807

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) tinzaparin, dosage regimen not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reviparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tinzaparin
Number of subjects: 0
Study: 9141585

Group type: EXPERIMENTAL
Intervention: SR 49059 (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SR 49059
Number of subjects: 12
Study: 8263640

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 16 mg preoperatively and three placebo postoperative doses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 16 mg preoperatively and three 8-mg postoperative doses
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3300664

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30265070

Group type: EXPERIMENTAL
Intervention: Integrative Tinnitus Management (ITM)
Number of subjects: 30
Study: 29362263

Group type: EXPERIMENTAL
Intervention: ABA infant feeding intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26071390

Group type: EXPERIMENTAL
Intervention: Brief risk reduction counselling at the time of HIV testing
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Baseline presence of Trichomonas vaginalis (TV)
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Baseline presence of chlamydia
Number of subjects: 1704

Group type: EXPERIMENTAL
Intervention: Baseline presence of HIV
Number of subjects: 1704
Study: 26311415

Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (LD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prasugrel loading dose (LD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ticagrelor and Prasugrel
Number of subjects: 24
Study: 23092692

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (GG)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Multispecies combination containing Lactobacillus rhamnosus GG
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21636731

Group type: EXPERIMENTAL
Intervention: Highly attractive other-sex targets
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Highly attractive same-sex targets
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Participants with high self-esteem
Number of subjects: 3
Study: 17531989

Group type: EXPERIMENTAL
Intervention: GnRH analogue and rFSH and rLH (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: GnRH analogue and rFSH without further LH addition (Group B)
Number of subjects: 84
Study: 16487108

Group type: EXPERIMENTAL
Intervention: Proderm (Pro‐Q in the USA) moisturizer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (22 healthy subjects)
Number of subjects: 24
Study: 14725658

Group type: EXPERIMENTAL
Intervention: 532-nm Nd:YAG laser at a fluence of 20 J/cm2 and a pulse duration of 50 ms
Number of subjects: 10

Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser at a fluence of 25 J/cm2 and a pulse duration of 40 ms
Number of subjects: 10
Study: 10861155

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 3 microg/ml (60 microg) fentanyl
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 84
Study: 9346454

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8121733

Group type: EXPERIMENTAL
Intervention: Aminophylline (Am)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 31
Study: 2552717

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 0
Study: 790890

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 0
Study: 31182293

Group type: EXPERIMENTAL
Intervention: Weight loss intervention during the holiday period
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Self-weighing frequency during the holiday period
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Longer intervention engagement during the holiday period
Number of subjects: 171
Study: 27629796

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 117
Study: 26541658

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg q8 h orally for 7 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study: 24368695

Group type: EXPERIMENTAL
Intervention: Music aerobic exercise (MAE) for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no MAE exercise)
Number of subjects: 47
Study: 21964491

Group type: EXPERIMENTAL
Intervention: G‐CSF (300 μg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19260880

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 182

Group type: COMPARATOR
Intervention: Delayed surgery (watchful waiting)
Number of subjects: 182
Study: 17763439

Group type: COMPARATOR
Intervention: Infliximab 3 mg/kg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg (after crossover from placebo)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg
Number of subjects: 122
Study: 16143712

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 12010361

Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC) treatment in the presence of M184V mutation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3TC treatment
Number of subjects: 0
Study: 9656043

Group type: EXPERIMENTAL
Intervention: Back massage (6 minutes)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined muscle relaxation, mental imagery, and music audiotape (7.5 minutes)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual nursing care (control group)
Number of subjects: 69
Study: 8738667

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3 g/day
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 2040133

Group type: EXPERIMENTAL
Intervention: Geriatric patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy young subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geriatric patients and healthy subjects
Number of subjects: 0
Study: 7027432

Group type: EXPERIMENTAL
Intervention: HP 549 (isoxepac) 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indomethacin 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aspirin 3 g
Number of subjects: 12
Study: 31785775

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 4859

Group type: EXPERIMENTAL
Intervention: Dabigatran discontinuation without switching to another oral anticoagulant
Number of subjects: 4859

Group type: EXPERIMENTAL
Intervention: Dabigatran discontinuation with switching to another oral anticoagulant
Number of subjects: 4859
Study: 30553687

Group type: EXPERIMENTAL
Intervention: Selective referral strategy using CCTA
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Direct referral strategy using ICA
Number of subjects: 1631
Study: 28229278

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD; containing 170 mg calcium and 500 IU/250 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 170 mg calcium and no vitamin D/250 mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD)
Number of subjects: 100
Study: 26004966

Group type: EXPERIMENTAL
Intervention: Lidocaine in tumescent solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prilocaine in tumescent solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine in tumescent solution
Number of subjects: 90
Study: 23110508

Group type: EXPERIMENTAL
Intervention: Usual exposure CsA (n=33)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reduced exposure CsA (n=42)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 21641345

Group type: EXPERIMENTAL
Intervention: SLV320 1.25 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SLV320 3.75 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SLV320 7.5 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SLV320 15 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19458428

Group type: EXPERIMENTAL
Intervention: Glycerin poultice applied to the flexor digitorum profundus in the middle phalanx of the little finger (GFML)
Number of subjects: 22
Study: 16293377

Group type: EXPERIMENTAL
Intervention: Educational lectures (study group, n=62)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No educational lectures (control group, n=63)
Number of subjects: 125
Study: 15283863

Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU) assessment
Number of subjects: 442
Study: 10930154

Group type: EXPERIMENTAL
Intervention: Antenatal monotherapy predominantly with zidovudine (ZDV)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Prior preterm birth
Number of subjects: 497

Group type: COMPARATOR
Intervention: Multiple gestation
Number of subjects: 497

Group type: COMPARATOR
Intervention: Antenatal alcohol use
Number of subjects: 497

Group type: COMPARATOR
Intervention: Antenatal diagnosis of genital herpes
Number of subjects: 497

Group type: COMPARATOR
Intervention: Antenatal diagnosis of pre-eclampsia
Number of subjects: 497

Group type: COMPARATOR
Intervention: Baseline HIV culture titer
Number of subjects: 497

Group type: COMPARATOR
Intervention: Antenatal cigarette use
Number of subjects: 497
Study: 1461630

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (800 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (160 mg/day)
Number of subjects: 34
Study: 6130082

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 30618048

Group type: EXPERIMENTAL
Intervention: Shared decision-making tools (SDMTs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no SDMT)
Number of subjects: 50
Study: 28597911

Group type: EXPERIMENTAL
Intervention: CoE‐IS‐Rifamate (Isoniazid/Rifampin 150/300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: native‐Rifamate
Number of subjects: 12
Study: 26663387

Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 43
Study: 24882155

Group type: EXPERIMENTAL
Intervention: MDMA (1.5mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20IU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MDMA (0.75mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 14
Study: 23210383

Group type: EXPERIMENTAL
Intervention: 16-week Matrix treatment
Number of subjects: 871

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 871
Study: 21030727

Group type: EXPERIMENTAL
Intervention: Nonweight-bearing ankle exercises
Number of subjects: 19

Group type: COMPARATOR
Intervention: Previous care regimen (Control)
Number of subjects: 19
Study: 18595289

Group type: EXPERIMENTAL
Intervention: Training procedure incorporating feedback and role‐play practice
Number of subjects: 8
Study: 15830647

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12876474

Group type: EXPERIMENTAL
Intervention: Electromagnetic field emitted by mobile phones, duration of exposure not specified.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used).
Number of subjects: 78
Study: 10593227

Group type: EXPERIMENTAL
Intervention: Multiple frequency bioelectrical impedance analysis (MFBIA) using the Cole model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple frequency bioelectrical impedance analysis (MFBIA) using the inductor circuit model (ICM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analogue circuit model (not specified as intervention)
Number of subjects: 0
Study: 8767244

Group type: EXPERIMENTAL
Intervention: Atracurium (5 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vecuronium (1 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pancuronium (1 mg)
Number of subjects: 64
Study: 1951158

Group type: EXPERIMENTAL
Intervention: 1.1 g carbohydrate/kg body mass (LC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.2 g carbohydrate/kg body mass (HC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 6374306

Group type: EXPERIMENTAL
Intervention: Formaldehyde gas (0.1, 1, and 3 ppm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Room-air placebo
Number of subjects: 13
Study: 31362189

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM)
Number of subjects: 171
Study: 29860341

Group type: EXPERIMENTAL
Intervention: Dexamethasone/vincristine pulse therapy during maintenance therapy in the standard risk group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive l-asparaginase therapy in the intermediate risk group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vincristine intensification in the high risk group
Number of subjects: 0
Study: 26036221

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (TLC)
Number of subjects: 59
Study: 24608864

Group type: EXPERIMENTAL
Intervention: Tablet-PC education
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (Tablet-PC and Conventional)
Number of subjects: 64
Study: 23308123

Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Twice-weekly balance and tone training
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study: 21824594

Group type: EXPERIMENTAL
Intervention: Double contrast-enhanced ultrasound (DCUS)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 162
Study: 19005929

Group type: EXPERIMENTAL
Intervention: Cheerfulness Training
Number of subjects: 0
Study: 15923407

Group type: EXPERIMENTAL
Intervention: Dual combinations of HIV-1 reverse transcriptase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple combinations of HIV-1 reverse transcriptase inhibitors
Number of subjects: 0
Study: 12859533

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557

Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 557
Study: 11094033

Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transdermal estradiol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 27
Study: 8853164

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 1642879

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (vinblastine, mitomycin, cisplatin, and bleomycin) and radiotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy (cisplatin and bleomycin) and radiotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Radiotherapy alone (70 Gy)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 90
Study: 6303264

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.3 to 4 mg/kg)
Number of subjects: 0
Study: 31425585

Group type: COMPARATOR
Intervention: CSSO during creep-feeding (CF) at 80 g/d per steer
Number of subjects: 64

Group type: COMPARATOR
Intervention: CSSO during preconditioning (PC) at 150 g/d per steer
Number of subjects: 64

Group type: COMPARATOR
Intervention: CSSO during PC
Number of subjects: 64

Group type: COMPARATOR
Intervention: CSSO during CF
Number of subjects: 64

Group type: COMPARATOR
Intervention: CSSO (both CF and PC)
Number of subjects: 64
Study: 29504733

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 69
Study: 26670991

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 15

Group type: COMPARATOR
Intervention: Uncaffeinated energy drink
Number of subjects: 15
Study: 25015021

Group type: EXPERIMENTAL
Intervention: YOUNG (aged 18-28 years)
Number of subjects: 12157

Group type: COMPARATOR
Intervention: OLD (aged 49-60 years)
Number of subjects: 12157

Group type: COMPARATOR
Intervention: BABIES (cord blood units)
Number of subjects: 12157
Study: 22192060

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia (PR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia (SR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sevoflurane-propofol-based anesthesia (SPR)
Number of subjects: 90
Study: 20071702

Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage for 4 to 6 weeks, followed by surgery
Number of subjects: 202

Group type: COMPARATOR
Intervention: Early surgery within 1 week after diagnosis
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Preoperative biliary drainage
Number of subjects: 202

Group type: COMPARATOR
Intervention: Early surgery
Number of subjects: 202
Study: 17377256

Group type: EXPERIMENTAL
Intervention: Fully immersed virtual reality (VR) environment using a head mounted display (HMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partially immersed (computer screen) VR environment
Number of subjects: 0